Our results are consistent with those of Pore et al. [28], who recently reported a correlation between increasing CAM-L counts, lowered CTC counts, and pathologic complete response (pCR) in breast cancer patients undergoing neoadjuvant chemotherapy (NAC) [28]. Here, CAMLG is linked to breast carcinoma.